A single‐nucleotide polymorphism in the TP53 and MDM‐2 gene modifies breast cancer risk in an ethnic Arab population

Breast cancer is the most common oncological disease in women worldwide. Genetic predisposition to breast cancer can be associated with single‐nucleotide polymorphisms (SNPs), which are observed in many women. Such gene polymorphisms, in combination with nutritional and environmental factors, can affect breast cancer development. The tumor suppressor TP53 and its negative regulator MDM2 play crucial roles in carcinogenesis. Previous case–control studies have revealed that TP53 72Arg > Pro and MDM2 309T > G polymorphisms contribute to the risk of common cancers. However, the relationship between these two functional polymorphisms and breast cancer susceptibility in the Saudi population has not been explored. In this study, we performed a case–control study of patients with breast cancer and healthy controls in a Saudi population using TaqMan‐based real‐time PCR. We found an increased breast cancer risk associated with the MDM2 GG [odds ratio (OR) = 2.79, 95% confidence interval (CI) = 2.04–3.92] and TG [OR = 1.43, 95% CI = 1.12–2.02] genotypes. An increased risk was also associated with the TP53 Pro/Pro genotype (OR = 2.19, 95% CI = 1.54–3.06) compared with the Arg/Arg genotype. The gene–gene interaction of MDM2 and TP53 polymorphisms increased breast cancer risk in a multiplicative manner (OR for the presence of both MDM2 GG and TP53 Pro/Pro genotypes = 7.71, 95% CI = 3.49–17.54). These findings suggest that polymorphisms of MDM2 and TP53 genes may be a genetic modifier for developing breast cancer in this ethnic population in the Arab world.

[1]  A. Alshatwi,et al.  Genetic Variation in IL‐6 and TNF‐α Genes with Risk of Breast Cancer in a Saudi Population‐based Case–Control Study , 2012, The breast journal.

[2]  S. Masood.  Expanded Role of Cytopathology in Breast Cancer Diagnosis, Therapy and Research: The Impact of Fine Needle Aspiration Biopsy and Imprint Cytology , 2012, The breast journal.

[3]  A. Alshatwi.  Breast cancer risk, dietary intake, and methylenetetrahydrofolate reductase (MTHFR)single nucleotide polymorphisms. , 2010, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[4]  Thilo Dörk,et al.  Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients , 2009, Breast Cancer Research.

[5]  Z. Tian,et al.  Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. , 2009, Leukemia research.

[6]  L. Cai,et al.  TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. , 2009, Archives of medical research.

[7]  R. Greil,et al.  MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Qattan,et al.  Gene expression profiling in women with breast cancer in a Saudi population. , 2008, Saudi medical journal.

[9]  K. Hoang-Xuan,et al.  Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors , 2008, Brain Research.

[10]  M. Olivier,et al.  Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. , 2008, Cancer letters.

[11]  K. Sabapathy,et al.  MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. , 2008, European journal of cancer.

[12]  K. Roemer,et al.  MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians , 2008, BMC Cancer.

[13]  Ali Al-Zahrani,et al.  Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience , 2007, BMC Cancer.

[14]  Hongbing Shen,et al.  MDM2 Promoter Polymorphism SNP309 Contributes to Tumor Susceptibility: Evidence from 21 Case-Control Studies , 2007, Cancer Epidemiology Biomarkers & Prevention.

[15]  T. Dörk,et al.  Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. , 2007, Cancer research.

[16]  Wen Tan,et al.  Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. , 2007, Carcinogenesis.

[17]  W. Hait,et al.  Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. , 2007, Cancer research.

[18]  David J. Hunter,et al.  The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies , 2006, Cancer Causes & Control.

[19]  L. J. Veer,et al.  The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes , 2007, European Journal of Human Genetics.

[20]  Hongbing Shen,et al.  MDM 2 Promoter Polymorphism SNP 309 Contributes to Tumor Susceptibility : Evidence from 21 Case-Control Studies , 2007 .

[21]  D. Eccles,et al.  No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. , 2006, Cancer letters.

[22]  Wen Tan,et al.  Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.

[23]  C. Bonaïti‐pellié,et al.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.

[24]  W. Tan,et al.  The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. , 2005, Cancer research.

[25]  L. Aaltonen,et al.  The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck , 2005, Journal of Medical Genetics.

[26]  W. Tan,et al.  The Role of P 53 and MDM 2 Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma , 2005 .

[27]  L. Aaltonen,et al.  The MDM 2 promoter polymorphism SNP 309 T R G and the risk of uterine leiomyosarcoma , colorectal cancer , and squamous cell carcinoma of the head and neck , 2005 .

[28]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[29]  R. Kreienberg,et al.  Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines , 1994, Human Genetics.

[30]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[31]  K. Livak,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay. , 1999, Genetic analysis : biomolecular engineering.

[32]  Miranda Thomas,et al.  Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.

[33]  T Foitzi,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .

[34]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[35]  D. Malkin,et al.  p53 and the Li-Fraumeni syndrome. , 1993, Cancer genetics and cytogenetics.

[36]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[37]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.